Author Search Results :: UTM Library Massive Scholar Tracking

1

Risk Factors and Risk Stratification of Thromboembolic Risk in Patients with Multiple Myeloma by Roza Chaireti, Hareth Nahi

Published 2022-08-01

Get full text

Article

2

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. by Hareth Nahi, Michael Chrobok, Charlotte Gran, Johan Lund, Astrid Gruber, Gösta Gahrton, Per Ljungman, Arnika Kathleen Wagner, Evren Alici

Published 2019-01-01

Get full text

Article

3

Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden by Katarina Uttervall, Love Tätting, Konstantinos Lemonakis, Mousa Majd, Jacob Crafoord, Mikael Olsson, Ulf‐Henrik Mellqvist, Markus Hansson, Hareth Nahi

Published 2024-04-01

Get full text

Article

4

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. by Adil Doganay Duru, Tolga Sutlu, Ann Wallblom, Katarina Uttervall, Johan Lund, Birgitta Stellan, Gösta Gahrton, Hareth Nahi, Evren Alici

Published 2015-01-01

Get full text

Article

5

Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma by Hareth Nahi, Gabriel Afram, Katarina Uttervall, Sandra Lockmer, Love Tätting, Gösta Gahrton, Muhammad Kashif, Evren Alici, Olga Stromberg, Monika Klimkowska, Johan Lund

Published 2023-11-01

Get full text

Article

6

An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients by Hareth Nahi, Hans Hägglund, Thomas Ahlgren, Per Bernell, Mats Hardling, Karin Karlsson, Vladimir Lj Lazarevic, Mats Linderholm, Bengt Smedmyr, Maria Åström, Helene Hallböök

Published 2008-11-01

Get full text

Article

7

Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry by Cecilie Hveding Blimark, Ingemar Turesson, Anna Genell, Lucia Ahlberg, Bo Björkstrand, Kristina Carlson, Karin Forsberg, Gunnar Juliusson, Olle Linder, Ulf-Henrik Mellqvist, Hareth Nahi, Sigurdur Y. Kristinsson, for the Swedish Myeloma Registry

Published 2018-03-01

Get full text

Article

8

P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OST... by Michael Gundesen, Fredrik Schjesvold, Annette Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Elena Todorescu, Bo Amdi Jensen, Tobias S. Slørdahl, Jon Thor Asmussen, Hareth Nahi, Anders Waage, Niels Abildgaard, Thomas Lund

Published 2023-08-01

Get full text

Article

9

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY by Manisha Bhutani, Alfred Garfall, Katarina Uttervall, Saad Z Usmani, Lionel Karlin, Lotfi Benboubker, Hareth Nahi, Jesús San Miguel, Danielle Trancucci, Keqin Qi, Tara Stephenson, Alfredo Perales-Puchalt, Katherine Chastain, Ajai Chari

Published 2023-08-01

Get full text

Article

10

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study by Göran Wålinder, Anna Genell, Gunnar Juliusson, Ronald Svensson, Antonio Izarra Santamaria, Jacob Crafoord, Kristina Carlson, Dorota Knut‐Bojanowska, Ljupco Veskovski, Birgitta Lauri, Johan Lund, Ingemar Turesson, Markus Hansson, Cecilie Hveding Blimark, Hareth Nahi

Published 2022-11-01

Get full text

Article

11

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network by Philippe Moreau, Pieter Sonneveld, Mario Boccadoro, Gordon Cook, Ma Victoria Mateos, Hareth Nahi, Hartmut Goldschmidt, Meletios A. Dimopoulos, Paulo Lucio, Joan Bladé, Michel Delforge, Roman Hajek, Heinz Ludwig, Thierry Facon, Jesus F. San Miguel, Hermann Einsele

Published 2019-12-01

Get full text

Article

12

Potential value of pre-planned imaging of bone disease in multiple myeloma by Michael T. Gundesen, Jon Thor Asmussen, Fredrik Schjesvold, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias S. Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Thomas Lund, Nordic Myeloma Study Group

Published 2023-07-01

Get full text

Article

13

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease by Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold, Nordic Myeloma Study Group

Published 2024-04-01

Get full text

Article

14

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression by Mina Ali, Ram Ajore, Anna-Karin Wihlborg, Abhishek Niroula, Bhairavi Swaminathan, Ellinor Johnsson, Owen W Stephens, Gareth Morgan, Tobias Meissner, Ingemar Turesson, Hartmut Goldschmidt, Ulf-Henrik Mellqvist, Urban Gullberg, Markus Hansson, Kari Hemminki, Hareth Nahi, Anders Waage, Niels Weinhold, Björn Nilsson

Published 2018-04-01

Get full text

Article

15

$Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)$

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO) by Jesus San-Miguel, Saad Z. Usmani, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Andrew Farnsworth, Hareth Nahi, Ajai Chari

Published 2020-04-01

Get full text

Article

16

Direct evidence for a polygenic etiology in familial multiple myeloma by Britt-Marie Halvarsson, Anna-Karin Wihlborg, Mina Ali, Konstantinos Lemonakis, Ellinor Johnsson, Abhishek Niroula, Carrie Cibulskis, Niels Weinhold, Asta Försti, Evren Alici, Christian Langer, Michael Pfreundschuh, Hartmut Goldschmidt, Ulf-Henrik Mellqvist, Ingemar Turesson, Anders Waage, Kari Hemminki, Todd Golub, Hareth Nahi, Urban Gullberg, Markus Hansson, Björn Nilsson

Published 2017-04-01

Get full text

Article

17

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Pa... by Nico Gagelmann, Diderik-Jan Eikema, Simona Iacobelli, Linda Koster, Hareth Nahi, Anne-Marie Stoppa, Tamás Masszi, Denis Caillot, Stig Lenhoff, Miklos Udvardy, Charles Crawley, William Arcese, Clara Mariette, Ann Hunter, Xavier Leleu, Martin Schipperus, Michel Delforge, Pietro Pioltelli, John A. Snowden, Maija Itälä-Remes, Maurizio Musso, Anja van Biezen, Laurent Garderet, Nicolaus Kröger

Published 2018-05-01

Get full text

Article

18

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MY... by Raija Silvennoinen, Anu Partanen, Anders Waage, Valdas Pečeliūnas, Fredrik Schjesvold, Pekka Anttila, Katarina Uttervall, Marjaana Säily, Mervi Putkonen, Kristina Carlson, Einar Haukas, Marja Sankelo, Damian Szatkowski, Markus Hansson, Anu Marttila, Per Axelsson, Ronald Svensson, Birgitta Lauri, Maija Mikkola, Conny Karlsson, Johanna Abelsson, Erik Ahlstrand, Anu Sikiö, Monika Klimkowska, Reda Matuzeviciene, Mona Hoyseter Fenstad, Sorella Ilveskero, Hareth Nahi

Published 2023-08-01

Get full text

Article

19

$Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma$